Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients

Area of Science:

• Pharmacology
• Cardiology
• Drug Metabolism

Background:

• Levosimendan is a key treatment for acute heart failure.
• Its active metabolite, OR-1896, is formed based on individual acetylator status.
• Understanding this relationship is crucial for optimizing heart failure therapy.

Purpose of the Study:

• To investigate the influence of acetylator status on hemodynamic responses to levosimendan.
• To determine if rapid or slow acetylator phenotypes alter levosimendan's efficacy.

Main Methods:

• Forty-one patients with NYHA class III-IV heart failure were categorized into rapid and slow acetylators using population kinetic modeling.
• Invasive hemodynamics and serial plasma concentrations of levosimendan and its metabolites were monitored.
• Acetylator status was determined via population kinetic modeling.

Main Results:

• Levosimendan administration resulted in sustained increases in heart rate and cardiac output, and decreases in pulmonary capillary wedge pressure (PCWP) and blood pressure for 24 hours post-infusion.
• While OR-1896 levels were higher in rapid acetylators, the overall hemodynamic effects, including changes in cardiac output and PCWP, were comparable between rapid and slow acetylator groups.
• Levosimendan levels were undetectable at 24 hours, with OR-1896 levels approximately twofold higher in rapid acetylators.

Conclusions:

• The hemodynamic effects of levosimendan in patients with acute heart failure are consistent regardless of acetylator status.
• Levosimendan's therapeutic impact on hemodynamics is not significantly modulated by individual acetylator phenotypes.